menu
    • menu
    [{"orgOrder":0,"company":"Cambium Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CAM-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cambium Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambium Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cambium Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cambium Bio","sponsor":"Aventacell Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"CAM-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cambium Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambium Bio \/ Aventacell Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Cambium Bio \/ Aventacell Biomedical"}]

    Find Clinical Drug Pipeline Developments & Deals by Cambium Bio

    Menu

    Cambium Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Sever...

                            Details : CAM-101 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 31, 2025

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Aventacell Biomedical

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cambium Bio Successfully Closes A$3.0M Financing Round

                            Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Aventacell Biomedical

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed

                            Cambium Bio

                            Australia arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Massachusetts Eye and Ear Infirmary | Oregon Health and Science University | University of Michigan | Duke University | Stanford University | University of Minnesota

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

                            Details : CAM-101 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 30, 2018

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Massachusetts Eye and Ear Infirmary | Oregon Health and Science University | University of Michigan | Duke University | Stanford University | University of Minnesota

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth